Amgen Inc. (AMGN)
AMGN · Health Care · 
United States
Amgen Inc. (AMGN) is a US company in the Health Care sector. The stock has its largest weight in CIND (Dow Jones), at 5.21%. Anyone who holds an ETF containing Amgen also has an indirect stake in the company.
Data and Charts: Amgen
Key Data for Amgen
Amgen Stock Price Chart
The Amgen chart shows daily closing prices and is set to the current year by default. The stock is up 42.4% year to date and up 59.6% over twelve months. The last recorded close on October 30, 2026, was $466.01, at 100% of the 52-week range.
Price series from our database since Jul 11, 2024, 580 daily values.
Amgen Stock Performance
| Year to date | +42.4% | 1 year | +59.6% |
|---|---|---|---|
| 1 month | +10.6% | 3 months | +21.0% |
| Calendar year 2025 | +25.6% |
Measured in euros, Amgen is up 49.7% year to date and up 65.0% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Amgen
Amgen Connections
The map shows how Amgen connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- Dow Jones Index · contains
- MSCI USA Health Care Index · contains
- MSCI World Health Care Index · contains
- United States Country · domicile
- XUHL ETF · holds
- CIND ETF · holds
- XUHC ETF · holds
- XDWH ETF · holds
- SPFS ETF · holds
- Health Care Sector · sector
- Gilead Sciences Stock · similar ETF exposure
- Vertex Pharmaceuticals Incorporated Stock · similar ETF exposure
What ETF Is Amgen In?
Amgen has very high ETF coverage and is held by 26 of the 104 ETFs we track, which together follow 13 indices. That puts the stock in more ETFs than 94.3% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| CIND | Dow Jones | 5.21% | €52.10 |
| XUHL / XUHC | MSCI USA Health Care | 3.71% | €37.05 |
| SPFS | MSCI World Health Care | 2.75% | €27.46 |
| XDWH | MSCI World Health Care | 2.74% | €27.43 |
| 2B7K | MSCI World SRI | 1.14% | €11.40 |
| EXXT | Nasdaq 100 | 1.08% | €10.80 |
| XNAS / XNA1 | Nasdaq 100 | 1.08% | €10.79 |
| SPYL / SPY5 | S&P 500 | 0.38% | €3.76 |
| XD9U / XD9D | MSCI USA | 0.37% | €3.73 |
| SXR8 | S&P 500 | 0.37% | €3.70 |
| XDEB | MSCI World Minimum Volatility | 0.35% | €3.47 |
| XDWD / XDWL | MSCI World | 0.27% | €2.73 |
| EUNL | MSCI World | 0.27% | €2.70 |
| SWWD | MSCI World | 0.27% | €2.68 |
| SPPW | MSCI World | 0.27% | €2.68 |
| SPYY | MSCI ACWI | 0.24% | €2.44 |
| WIMI | MSCI World IMI | 0.24% | €2.43 |
| IUSQ | MSCI ACWI | 0.24% | €2.40 |
| XDEW | S&P 500 Equal Weight | 0.23% | €2.29 |
| SPYI / SPSA | MSCI ACWI IMI | 0.23% | €2.25 |
The last column shows how much of €1,000 in one of these funds goes to Amgen, based on each fund's latest holdings list.
US-listed ETFs holding Amgen (weight per latest SEC filing): SCHD 4.70%, QQQM 1.02%, QQQ 0.85%, VYM 0.78%, ONEQ 0.50%, IVV 0.30%, SPY 0.30%, VOO 0.30%, VTI 0.27%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Amgen Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Amgen had a weight of 0.29% on Sep 30, 2019 and 0.27% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.34% on Mar 31, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Amgen overlaps with the rest of a portfolio.
Which Tracked Investors Hold Amgen?
Amgen is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Amgen increased its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 21,869 | $8M | increased by 7,095 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
Stocks With ETF Exposure Similar to Amgen
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Amgen | – | – | +59.6% | 27.7% | 21.0% | +10.0% |
 Vertex Pharmaceuticals Incorporated | 25 | +0.64 | +33.1% | 31.8% | 32.9% | +8.9% |
 Regeneron Pharmaceuticals | 24 | – | +41.9% | 36.5% | 31.4% | +1.0% |
 Gilead Sciences | 25 | +0.58 | +44.1% | 26.8% | 28.9% | +2.4% |
 IDEXX Laboratories | 24 | – | -12.3% | 36.6% | 24.6% | +10.4% |
 Intuitive Surgical | 23 | – | -18.5% | 34.2% | 28.4% | +20.5% |
 DexCom | 23 | – | +20.7% | 40.8% | 17.9% | +15.6% |
 Edwards Lifesciences Corporation | 22 | – | +10.2% | 25.0% | 17.7% | +11.5% |
 HCA Healthcare Inc | 22 | – | +1.4% | 29.0% | 9.0% | +7.1% |
These stocks reach a portfolio through largely the same funds as Amgen. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Amgen
Amgen Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 28.2 | 6.7 | 23.8% |
| FY ended Dec 2024 | 33.4 | 4.1 | 12.2% |
| FY ended Dec 2025 | 36.8 | 7.7 | 21.0% |
Latest Patents Granted to Amgen
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, Amgen received 112 utility patents and 4 design patents. That is 0.035% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 4.9 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12774330 B2 | Continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes | C07K Chemistry; metallurgy | ||
| US 12770328 B2 | 3D particle imaging in pharmaceutical containers | G06T Image data processing and generation | ||
| US 12766252 B2 | Drug delivery device with sterile fluid flowpath and related method of assembly | A61M Human necessities | ||
| US 12760262 B2 | In-process verification of calibration status of pH probes | C12M Chemistry; metallurgy | ||
| US 12760057 B2 | Purification methods for carbohydrate-linked oligonucleotides | C07H Chemistry; metallurgy |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: AMGEN INC. Titles as published by the office; median time based on 68 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
Technical Analysis: Amgen
Amgen Risk Metrics
The close on Oct 30, 2026, was the highest since our series began on Jul 11, 2024. When the S&P 500 rose or fell 1%, Amgen moved 0.44% on average in the same direction (past 252 trading days). The correlation of 0.19, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Amgen.
What Amgen Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Royalty Pharma Plc Class A | +0.72 | |
| Vertex Pharmaceuticals Incorporated | +0.64 | |
| Pfizer Inc. | +0.63 | |
| AbbVie Inc. | +0.59 | |
| Gilead Sciences Inc. | +0.58 | |
| Eli Lilly and Company | +0.57 | |
| KAVA | -0.48 | |
| SOLV | -0.44 | |
| RAY | -0.39 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
